KR20230026337A - 간질의 치료에서 칸나비디올의 용도 - Google Patents

간질의 치료에서 칸나비디올의 용도 Download PDF

Info

Publication number
KR20230026337A
KR20230026337A KR1020227044124A KR20227044124A KR20230026337A KR 20230026337 A KR20230026337 A KR 20230026337A KR 1020227044124 A KR1020227044124 A KR 1020227044124A KR 20227044124 A KR20227044124 A KR 20227044124A KR 20230026337 A KR20230026337 A KR 20230026337A
Authority
KR
South Korea
Prior art keywords
cbd
caffeine
cannabidiol
dose
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227044124A
Other languages
English (en)
Korean (ko)
Inventor
지에 리
케빈 제임스 크레이그
다니엘 아담 체켓츠
데이비드 존 크리츨리
Original Assignee
지더블유 리서치 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지더블유 리서치 리미티드 filed Critical 지더블유 리서치 리미티드
Publication of KR20230026337A publication Critical patent/KR20230026337A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227044124A 2020-06-18 2021-06-16 간질의 치료에서 칸나비디올의 용도 Pending KR20230026337A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2009321.7A GB202009321D0 (en) 2020-06-18 2020-06-18 Use of cannabinoids in the treatment of epilepsy
GB2009321.7 2020-06-18
PCT/GB2021/051520 WO2021255446A1 (en) 2020-06-18 2021-06-16 Use of cannabidiol in the treatment of epilepsy

Publications (1)

Publication Number Publication Date
KR20230026337A true KR20230026337A (ko) 2023-02-24

Family

ID=71838306

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227044124A Pending KR20230026337A (ko) 2020-06-18 2021-06-16 간질의 치료에서 칸나비디올의 용도

Country Status (11)

Country Link
US (1) US20230225986A1 (https=)
EP (1) EP4167980B1 (https=)
JP (1) JP2023530500A (https=)
KR (1) KR20230026337A (https=)
CN (1) CN115916168A (https=)
AU (1) AU2021291128A1 (https=)
CA (1) CA3181694A1 (https=)
GB (2) GB202009321D0 (https=)
MX (1) MX2022016038A (https=)
TW (1) TW202214217A (https=)
WO (1) WO2021255446A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
AU2024300440A1 (en) * 2023-07-25 2026-03-12 Algorae Pharmaceuticals Ltd Compositions and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015308546A1 (en) * 2014-08-25 2017-04-13 Clk Consult V/ Carsten Leonhard Knudsen Device with compositions for delivery to the lungs, the oral mucosa and the brain
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US20180360771A1 (en) * 2017-06-14 2018-12-20 Yury Leon Shmerlis Cannabidiol chewing gum
GB2568471B (en) 2017-11-15 2022-04-13 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
CN109985042A (zh) * 2017-12-29 2019-07-09 汉义生物科技（北京）有限公司 一种含有大麻二酚或大麻提取物和咖啡因的组合物及其应用
US20200172841A1 (en) * 2018-12-04 2020-06-04 Donald F. Wilkes Alcohol-free wine beverage

Also Published As

Publication number Publication date
EP4167980A1 (en) 2023-04-26
AU2021291128A1 (en) 2022-12-01
CA3181694A1 (en) 2021-12-23
CN115916168A (zh) 2023-04-04
GB202009321D0 (en) 2020-08-05
TW202214217A (zh) 2022-04-16
WO2021255446A1 (en) 2021-12-23
MX2022016038A (es) 2023-02-02
GB202108690D0 (en) 2021-08-04
US20230225986A1 (en) 2023-07-20
GB2598187A (en) 2022-02-23
JP2023530500A (ja) 2023-07-18
EP4167980B1 (en) 2025-07-16

Similar Documents

Publication Publication Date Title
AU2021266209B2 (en) Theacrine-based supplement and method of use thereof
Fabiano et al. Paediatric pharmacology: remember the excipients
US8546342B2 (en) Composition for treating mental health disorders
US11707465B2 (en) Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine
US11925645B2 (en) Enhanced caffeinated beverage composition
US7476406B1 (en) Multifaceted weight control system
KR20230026337A (ko) 간질의 치료에서 칸나비디올의 용도
Kyriacou et al. Green tea catechins as perpetrators of drug pharmacokinetic interactions
Shell et al. A randomized, placebo-controlled trial of an amino acid preparation on timing and quality of sleep
JP7629453B2 (ja) 小児用トラゾドン組成物およびその治療法
CN115279197A (zh) 增强型含咖啡因饮料组合物
Yu et al. Pharmacokinetics and use‐testing of apalutamide prepared in aqueous food vehicles for alternative administration
KR101568044B1 (ko) 불안 및 스트레스 해소용 조성물
KR101864384B1 (ko) 콜린 알포세레이트를 유효성분으로 하는 쥐남의 치료, 개선 또는 예방용 조성물 및 방법
KR102531387B1 (ko) 홍경천 및 연자육을 포함하는 수면 장애 개선용 조성물
KR101841654B1 (ko) 콜린 알포세레이트를 유효성분으로 하는 신경병증성 통증의 치료, 개선 또는 예방용 조성물 및 방법
EP3651770B1 (en) Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine
AU2018101586A4 (en) Uses of polydatin
US20050069596A1 (en) Compositions and methods comprising kava and anti-anxiety compounds
JP7637357B2 (ja) 血管保護のためのターメリックオイルを含有する組成物、ならびにこのような組成物を含む飲食品および香料
CURRENT SAFETY ISSUES OF CURRENT INTEREST
HK1115341B (en) Composition for treating mental health disorders

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000